Properties (71)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
none reported
|
| gptkbp:annualVisitors |
held annually
|
| gptkbp:businessModel |
active efforts
|
| gptkbp:CEO |
gptkb:Paul_Friedman
|
| gptkbp:clinicalTrials |
ongoing
innovative designs multiple phases Phase 3 trials promising metabolic diseases various sites NASH and related conditions patient-centric approach results published in journals focused on liver health positive outcomes expected Madrigal's_Phase_2_study |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:communityEngagement |
active
|
| gptkbp:communityOutreach |
engaged in outreach programs
|
| gptkbp:communityPartnerships |
strategic alliances
|
| gptkbp:drugInterdiction |
navigating_FDA_process
|
| gptkbp:employees |
over 100
|
| gptkbp:financialPerformance |
reported quarterly
volatile |
| gptkbp:financials |
quarterly reports available
|
| gptkbp:focus |
liver diseases
|
| gptkbp:founded |
2011
|
| gptkbp:funding |
venture capital
|
| gptkbp:hasPrograms |
established
|
| gptkbp:hasResearchInterest |
conducted regularly
|
| gptkbp:headquarters |
gptkb:Waltham,_Massachusetts
|
| gptkbp:historicalResearch |
ongoing
ongoing research efforts |
| https://www.w3.org/2000/01/rdf-schema#label |
Madrigal Pharmaceuticals
|
| gptkbp:investmentFocus |
active
institutional investors regularly updated participates regularly proactive engagement |
| gptkbp:leadership |
experienced
|
| gptkbp:leads |
Madrigal's Resmetirom
|
| gptkbp:market |
global
approximately $1 billion fluctuates global market entry plans |
| gptkbp:marketingStrategy |
focused on innovation
|
| gptkbp:partnerships |
various pharmaceutical companies
strategic partnerships |
| gptkbp:patentCitation |
multiple patents filed
|
| gptkbp:portfolioCompany |
dedicated team
|
| gptkbp:productLine |
diverse pipeline
|
| gptkbp:products |
Resmetirom
|
| gptkbp:regulatoryCompliance |
FDA_approval_pending
submitted_to_FDA |
| gptkbp:research |
secured funding
|
| gptkbp:research_areas |
cardiometabolic diseases
|
| gptkbp:researchAreas |
non-alcoholic_steatohepatitis_(NASH)
|
| gptkbp:researchInterest |
published research
various initiatives with leading institutions awarded grants |
| gptkbp:scientificName |
renowned experts
|
| gptkbp:socialMediaPresence |
strong
|
| gptkbp:stockSymbol |
MDGL
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
multiple drug candidates
|
| gptkbp:type |
public company
|
| gptkbp:updates |
frequent
|
| gptkbp:website |
www.madrigalpharma.com
|